PMID- 25452672
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141202
LR  - 20231104
IS  - 0972-7531 (Print)
IS  - 0976-3260 (Electronic)
IS  - 0972-7531 (Linking)
VI  - 21
IP  - 4
DP  - 2014 Oct
TI  - Brain-Derived Neurotrophic Factor in children with Autism Spectrum Disorder.
PG  - 129-33
LID - 10.5214/ans.0972.7531.210403 [doi]
AB  - BACKGROUND: Autism Spectrum Disorder (ASD) is a complex neurobehavioral syndrome 
      with no known biomarker so far for early detection. It has been challenging, both 
      to classify typical autism and associate a suitable biomarker with clinical 
      phenotype spectrum. Brain-derived neurotrophic factor (BDNF) has emerged as a key 
      neurotrophin regulating synaptic plasticity, neuronal differentiation and 
      survival. PURPOSE: Recently, BDNF depletion is reported in neurodegenerative as 
      well as in psychiatric disorders, associated with severity of neurological 
      dysfunction. Role of BDNF as a biomarker in ASD is gaining significance. 
      Pre-clinical results have linked BDNF depletion in autism and mental retardation, 
      however, with conflicting findings. METHODS: In view of this, a preliminary study 
      was carried out to measure serum BDNF levels in 48 children with ASD and mental 
      retardation, and 29 age-matched controls. RESULTS: Serum BDNF levels were found 
      significantly higher (p<0.001) in atypical autistic subjects (clinically milder 
      phenotype) as compared to controls, but not in typical ASD cases (clinically 
      severe phenotype). BDNF levels were significantly lower in females with 
      typical/Rett Syndrome (p<0.05), but not in males with typical autism (p>0.1), as 
      compared to controls. Lower BDNF levels indicate impairment in neuroprotective 
      mechanism, while higher levels may imply a manifested protective response. 
      CONCLUSION: Our study highlights the differential BDNF response based on the 
      severity of neurobehavioral deficit, indicating a possible neuroprotective role 
      of this molecule and supporting its exploration in targeted therapy in ASD.
FAU - Kasarpalkar, Nikhil J
AU  - Kasarpalkar NJ
AD  - Department of Biochemistry;
FAU - Kothari, Sweta T
AU  - Kothari ST
AD  - Department of Virology;
FAU - Dave, Usha P
AU  - Dave UP
AD  - Haffkine Institute and Director- MILS International India, Mumbai.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Neurosci
JT  - Annals of neurosciences
JID - 101523367
PMC - PMC4248479
OTO - NOTNLM
OT  - BDNF
OT  - Biomarker
OT  - Disorder
COIS- Conflict of Interests: None: Source of funding: None.
EDAT- 2014/12/03 06:00
MHDA- 2014/12/03 06:01
PMCR- 2014/10/01
CRDT- 2014/12/03 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/07/25 00:00 [revised]
PHST- 2014/09/14 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2014/12/03 06:01 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - 210403 [pii]
AID - 10.5214/ans.0972.7531.210403 [doi]
PST - ppublish
SO  - Ann Neurosci. 2014 Oct;21(4):129-33. doi: 10.5214/ans.0972.7531.210403.